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PAA6
RACIAL DIFFERENCES IN PHARMACOTHERAPY AND HEALTH
CARE EXPENDITURES FOR THE TREATMENT OF ASTHMA IN
A MEDICAID POPULATION
Hawkins K1, Stanford RH2, Orsini LS3, Ozminkowski RJ1, Jiang C4
1The MEDSTAT Group, Inc, Ann Arbor, MI, USA; 2GlaxoSmithKline,
RTP, NC, USA; 3The MEDSTAT Group, Inc, Cambridge, MA, USA;
4The MEDSTAT Group, Inc, Santa Barbara, CA, USA
OBJECTIVES: To compare pharmacotherapy and health care
expenditures by race for asthma patients in a Medicaid popula-
tion. METHODS: This analysis used the MarketScan® claims
and eligibility data for a multistate Medicaid population between
1999–2000. Because Medicaid eligibility is updated monthly, 24
monthly ﬁles were constructed to capture all Medicaid asthmatic
patients in 1999 and 2000. Patients were included in the study
if they had an asthma diagnosis or prescription for an asthma-
related drug in any given month. Patients were grouped by race,
a variable often not found in health care claims data sets. Type
of pharmacotherapy, demographics, health status, health care
utilization, and expenditures were measured to assess differences
between the racial groups. Descriptive analysis was used to deter-
mine medication use and health care costs across racial cohorts.
RESULTS: A total of 2,724,008 subjects were eligible for eval-
uation over the 2 year observational period. Overall, patients
used 1.8 times as many rescue medications compared to long
term controller medications per month. Hispanics used 2.5 times
more rescue medications. African-Americans (AA) used 2 times
more rescue medications, and Caucasians used 1.6 times more
rescue medications. Compared to Caucasians, asthma-related
drug expenditures were 20% and 69% lower for AA and His-
panics respectively. However, asthma-related inpatient costs were
94% higher for AA and 58% higher for Hispanics compared to
Caucasians. Similarly, asthma-related emergency room (ER)
costs were 48% higher for AA and 13% higher for Hispanics
compared to Caucasians. Overall, the largest component of the
asthma care among all groups was pharmacotherapy, at 50% of
total asthma expenditures ($64 per month). CONCLUSIONS:
Long-term controller asthma medications were underused by all,
but more so among minorities. This difference in use was
reﬂected in the cost of inpatient and ER asthma care across the
racial cohorts.
PAA7
HEALTH CARE EXPENDITURES OF PATIENTS WITH
COMORBID ALLERGIC RHINITIS AND ASTHMA
Chang S1, Long S1, Leahy M2, Crown WH3
1Medstat, Washington, DC, USA; 2Aventis Pharmaceutical, Bridgewater,
NJ, USA; 3The MEDSTAT Group, Cambridge, MA, USA
OBJECTIVES: To review the health care expenditures of patients
with comorbid allergic rhinitis (AR) and asthma, and determine
if AR treatment offsets the costs of asthma of these patients.
METHODS: A retrospective analysis was performed using the
MarketScan claims databases. The study population consisted of
privately insured and Medicare patients diagnosed with AR (N
= 347,363) in 1999 or 2000. Patients with at least two outpa-
tient prescriptions for asthma medication, or a diagnosis of
asthma and at least one outpatient prescription for asthma med-
ication, were classiﬁed as having asthma. Asthma-related health
care expenditures were accumulated over a 12-month follow-up
period. Expenditures among treated AR patients were compared
to untreated AR patients. RESULTS: Approximately 16% of AR
patients had comorbid asthma. The majority (90.8%) of these
patients received at least one AR treatment of a nonsedating anti-
histamine, inhaled nasal corticosteroid, or inhaled antihistamine
during the 12 month follow-up period. Patients without AR
treatment had mean annual asthma-related emergency room
(ER), inpatient, and outpatient expenditures of $24 (127 S.D.),
$201 (3340 S.D.), and $240 (561 S.D.), respectively. Compared
to untreated AR patients, persons receiving AR treatment had
signiﬁcantly lower mean annual asthma-related costs (p < 0.05)
for ER, inpatient and outpatient expenditures, $18 (151 S.D.),
$114 (1575 S.D.), and $181 (588 S.D.), respectively. Costs 
of outpatient prescription drug for asthma were higher among
AR-treated patients than untreated ($447 vs. $355, p < 0.05),
nevertheless, mean total asthma costs for AR-treated patients
were $760 (1931 S.D.), signiﬁcantly lower than for untreated
patients, $820 (3515 S.D.). AR-treated asthma patients also had
lower asthma expenditures compared to the untreated after con-
trolling for differences in demographics, comorbidities, and
asthma severity. CONCLUSIONS: Asthma is a common comor-
bidity of AR. Use of AR drug treatment may offset some asthma
expenditures.
PAA8
THE EFFECT OF HAVING A PRIMARY CARE PROVIDER ON
ASTHMA HEALTH CARE EXPENDITURE AND HEALTH CARE
UTILIZATION
Nurmagambetov T,Atherly A,Williams S, Redd S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: To evaluate medical expenditures for asthma care
based on whether a health care plan requires enrolled members
to have a primary care provider (PCP). METHODS: The data
were drawn from the MEDSTAT MarketScan database. The
sample included 184,892 patients with either at least one hospi-
talization or at least two outpatient visits for asthma during
1998–2001. Approximately 51 percent (94150) of the sample
were enrolled in health plans requiring a PCP (PCP plans), while
the remainder were enrolled in plans not requiring a PCP (NPCP
plans). We used a log-linear regression analysis to examine dif-
ferences in expenditures between plan types, controlling for
gender, age, region, industry and dependent status. All differ-
ences are signiﬁcant at p < 0.001. RESULTS: Total per capita
medical expenditures were signiﬁcantly higher for NPCP ($730)
than for PCP plans ($598). Both hospital ($170 versus $88) and
outpatient ($355 versus $306) expenditures were signiﬁcantly
higher for NPCP than for PCP plans with no signiﬁcant differ-
ences in prescription drug expenditures ($205 versus $204). For
patients hospitalized at least once these differences in expendi-
tures were larger; with mean total expenditures of $7040 for
NPCP versus $5626 for PCP plans, and with 31 percent differ-
ences in hospitalization costs ($6084 versus $4640). On the
other hand, the average numbers of hospital readmissions for
asthma were signiﬁcantly higher (0.03 versus 0.02) for NPCP
than for PCP plans as was the average length of hospital stay
(4.02 versus 3.52 days). However, the number of outpatient visits
were signiﬁcantly lower for NPCP (5.67) than for PCP (5.97)
plans. CONCLUSION: Patients in PCP plans have fewer and
shorter hospitalizations and they visit outpatient clinics more fre-
quently. Although differential enrollment by severity cannot be
excluded, PCP plans not only cost less but might also provide
better asthma management for patients.
PAA9
ASTHMA-RELATED HEALTH CARE SERVICES 
UTILIZATION BY AFRICAN-AMERICANS IN A MEDICAID
POPULATION
Pawar VS, Smith MJ
West Virginia University, Morgantown, WV, USA
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Prior surveillance has shown that higher rates of morbidity and
mortality related to asthma occur among African-Americans
compared to other ethnic groups. OBJECTIVE: to assess uti-
lization and costs for medical services and prescription medica-
tions among African-American patients with asthma whom does
Medicaid cover. METHODS: Medical services claims with a
primary diagnosis code for asthma (ICD-9 CM 493) during cal-
endar year 2002 for recipients of African-American ethnicity
were extracted from a state Medicaid claims database. Asthma-
related prescription claims were extracted using unique and
anonymous recipient codes obtained from the medical claims.
Claims for recipients aged 65 years and older were excluded.
Cost data were from the perspective of Medicaid. RESULTS:
There were 654 African-American recipients identiﬁed with
asthma. Among these, the highest rates for asthma occurred
among males under 21 years (43 per 1000) and females over 20
years (38 per 1000). Medicaid paid over $570,000 for asthma-
related health care services for African-American recipients.
Mean costs per visit were $3409 for hospitalizations, $159 for
emergency department (ED) visits, and $102 for outpatient
visits. Compared to females, males had a higher rate of inpatient
admissions (32 per 10,000), ED visits (170 per 10,000), and out-
patient visits (68 per 1000) for asthma. Compared to children,
adults over 20 years had a higher rate of inpatient admissions
(30 per 10,000), ED visits (150 per 10,000), and outpatient visits
(68 per 1000) for asthma. The total cost for prescription med-
ications equaled approximately $256,000, at an average cost of
$49 per prescription. Of the prescription claims for asthma-
related medications, about 60% were for quick-relief medica-
tions and 40% were for maintenance drugs. Among claims for
maintenance drugs, most were for leukotriene inhibitors. CON-
CLUSIONS: Males utilized medical services more frequently
than females, as did adults compared to children. Quick-relief
medications accounted for most of the prescription claims.
PAA10
BUDGET IMPACT ANALYSIS: COMBINATION FLUTICASONE
AND SALMETEROL FOR ASTHMA
Mauskopf JA1, Shih T2, Baker T3, Borker R4, Stanford RH4, Jhingran P4
1RTI Health Solutions, Research Triangle Park, NC, USA; 2The
University of Texas M.D. Anderson Cancer Center, Houston,TX, USA;
3MEDTAP, Bethesda, MD, USA; 4GlaxoSmithKline, RTP, NC, USA
OBJECTIVES: The objective of this study was to estimate the
budget and health impact of increasing use of combination 
ﬂuticasone propionate and salmeterol (FS) in a managed care for-
mulary by adults with mild to moderate persistent asthma.
METHODS: An EXCEL-based model was developed to estimate
the impact of increasing use of FS in the mix of treatments used
for persistent asthma including ﬂuticasone proprionate (FP), sal-
meterol (SAL), other inhaled corticosteroids (ICS), leukotriene
modiﬁers (LTM), other combination therapies, and short-acting
beta-agonists (SABA). The analysis was conducted from a health
plan’s perspective. Efﬁcacy, adverse events, epidemiology, com-
pliance, and cost data were obtained from published estimates
including randomized controlled trials. The health plan was
assumed to have 1,000,000 members. Treatment mix for asthma
was based on market research data. An exponential relationship
between compliance and efﬁcacy was assumed for compliance
rates above thirty percent. RESULTS: A total of 29,050 persons
were estimated to seek treatment for persistent asthma in the
health plan. Model results comparing an FS market share of 25%
to one of 30% in the health plan show total asthma treatment
cost increases of $0.03/per member (all enrollees) per month
(PMPM) and $0.96/per asthmatic patient per month. The budget
impacts were accompanied by an annual increase of 56,555
rescue-free days and reduction of 155 exacerbations. Results are
sensitive to changes in drug costs, drugs used before FS, com-
pliance with asthma drugs, and the relationship between com-
pliance and efﬁcacy with PMPM changes ranging from a saving
of $0.01/PMPM to an increase of $0.06/PMPM for feasible alter-
native scenarios. CONCLUSION: An increase in market share
of FS will have a small impact on the overall budget of a health
plan in our base case and feasible alternative scenarios. This
budget increase will be accompanied by reductions in exacerba-
tions and other disease symptoms.
PAA11
EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE
MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO
MEDICAID POPULATION
Heaton PC, Guo JJ, Jang R, Cluxton RJ
University of Cincinnati, Cincinnati, OH, USA
OBJECTIVES: To determine the impact of leukotriene modiﬁers
on subsequent emergency room visits, hospitalizations and
steroid bursts; and to estimate whether leukotriene modiﬁer use
is cost-beneﬁcial. METHODS: A retrospective, longitudinal
study of 5541 adult asthmatic patients in the Ohio Medicaid
program used rate of adverse outcomes and logistic regression
to determine the impact of leukotriene modiﬁer use on three
outcome measures: emergency room visits, hospitalizations, or
steroid bursts. Propensity scores were used to control selection
bias inherent in drug treatment selection in natural databases. A
cost-beneﬁt analysis was also calculated. The cost-beneﬁt ratio
was deﬁned as the difference in asthma drug costs between the
leukotriene users and nonusers divided by the difference in
outcome costs between the users and nonusers. RESULTS:
Leukotriene modiﬁer users had 13.9 events per one hundred
patients versus the nonusers who had 11.1 events per one
hundred patients. In logistic regression models, the use of
leukotriene modiﬁers did not signiﬁcantly impact the odds of any
outcome measures: Emergency Room Visits OR 1.163, 95% CI
0.913–1.483; Hospitalizations OR 1.061, 95% CI 0.685–1.643;
Steroid Bursts OR 1.362, 95% CI 0.933–1.988. The mean cost
of all asthma drugs received by leukotriene modiﬁer users was
$327.19 and for nonusers was $186.70. The mean cost of all
outcome measures was $104.80 for leukotriene modiﬁer users
and $99.89 for nonusers. This resulted in a cost beneﬁt ratio
equal to 28.6. CONCLUSIONS: Logistic regression models
suggest that the use of leukotriene modiﬁers did not have a 
positive or negative signiﬁcant effect on any of the outcome vari-
ables. Leukotriene modiﬁer users did have higher rates of adverse
outcomes. The cost beneﬁt analysis shows that there was a total
net loss to Ohio Medicaid. The results suggest that leukotriene
modiﬁer users do not have improved outcomes or improved 
cost-beneﬁt when compared to nonusers.
PAA12
RESOURCE UTILIZATION (HOSPITAL AND PHYSICIAN
COST/VISITS) BEFORE AND AFTER INTRODUCTION OF THE
NEW TREATMENT GUIDELINES IN ASTHMA (1997) AND
ODDS OF BEING ON APPROPRIATE ASTHMA THERAPY
USING MULTIVARIATE LOGISTIC REGRESSION
Mehta R, Cady P
Idaho State University, Salt Lake City, UT, USA
OBJECTIVE: To evaluate the resource utilization after intro-
duction of new treatment guidelines in Asthma (1997).
METHODS: Paid claims for pharmacy services during the period
1994 through 2000 were collected. Chronic users (CUs): using
more than 10 canisters of beta-inhaler/year. Patients were further
categorized: CHBYAi (CUs, using some anti-inﬂammatory 
